Evidence map›Paper›PMID 39723838›Full record

ArticleJournal of virology2025

The persistent pool of HIV-1-infected cells is formed episodically during untreated infection.

Olivia D Council, Lynn Tyers, Matthew Moeser, Amy Sondgeroth, Ean Spielvogel, Brian D Richardson, Deelan Doolabh, Shuntai Zhou, Ann Emery, Nancie M Archin and 9 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Olivia D CouncilDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0009-0003-5139-4417
Lynn TyersDivision of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
Matthew MoeserLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Amy SondgerothLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ean SpielvogelLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Brian D RichardsonDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Deelan DoolabhDivision of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
Shuntai ZhouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8353-386X
Ann EmeryLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Nancie M ArchinUNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-7938-0389
Bonnie Shook-SaDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
David M MargolisUNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Salim S Abdool KarimCenter for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
Sergei Kosakovsky PondInstitute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Nigel GarrettCenter for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa.
Melissa-Rose AbrahamsDivision of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
Sarah B JosephDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Carolyn WilliamsonDivision of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Rondebosch, Western Cape, South Africa.
Ronald SwanstromLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7777-0773

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
An in integrated platform for multiomic analyses of pathogen and host data using scalable public infrastructureU24AI183870 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI Kelsey M Beavers, Maximilian Haeussler · 2024 to 2026
$10.2M
HIV Evolution Defines Virus-Host/Drug Interactions In Viremic and Aviremic PeopleR01AI140970 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ronald I Swanstrom, Shuntai Zhou · 2018 to 2026
$4.1M
Formation of the HIV-1 Latent ReservoirR01AI147849 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2020 to 2024
$3.0M
FIC NIH HHS D43 TW000231NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI140970NIAID NIH HHS R01 AI147849NIAID NIH HHS U19 AI051794NIAID NIH HHS U24 AI183870NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI164567Wellcome Trust
6 · The paper itself

Abstract

Previous studies have shown that the majority of long-lived cells harboring persistent HIV-1 proviral genomes originates from viruses circulating in the year prior to antiretroviral therapy (ART) initiation, but a smaller proportion originates from viruses circulating much earlier in untreated infection. These observations suggest that discrete biological factors influence the entry and persistence of viruses into the persistent proviral pool, and there may be periods earlier in untreated infection with increased seeding. Therefore, we examined the timing of formation of the long-lived pool of infected cells that persists during ART in seven women (after a median of 5.1 years of suppressive ART) by comparing the phylogenetic distance between unique 3' half genome on-ART proviral sequences and longitudinally sampled pre-ART viral RNA sequences, focusing on the period >1 year prior to ART initiation (i.e., the "early" proviral pool). We constructed models of continuous entry into the persistent proviral pool prior to ART initiation and analyzed the fit of our experimentally derived data to these models. We found that the pattern of persistent proviral pool formation in five of seven participants is incongruent with a model of continuous entry, implying that persistent proviral pool formation can occur episodically during untreated infection. Notably, increased entry into the persistent proviral pool was not universally observed during acute infection, and the timing of enhanced early entry differed across the participants.IMPORTANCECells harboring HIV-1 proviruses that persist on antiretroviral therapy (ART) constitute the main barrier to an HIV-1 cure. Recent work has elucidated that the majority of persisting proviruses harbor HIV-1 variants circulating near the time of ART initiation, whether the proviruses are intact or defective, though a portion forms earlier in untreated infection. We examined the formation of the "early-forming" persistent proviral pool and found that in 5/7 participants, persistent proviral pool formation was episodic, rather than continuous, suggesting that there are host/biological factors that periodically enhance the formation of the persistent proviral pool. Further characterization of these factors will aid in the development of methods to abrogate their effect, thereby reducing the size of the persistent proviral pool.

Indexed as

HIV-1HIV InfectionsProvirusesAdultCD4-Positive T-LymphocytesFemaleHumansLongitudinal StudiesPhylogenyRNA, ViralViral LoadRNA, ViralHIV-1reservoirsequencing

Identifiers

PMID39723838
PMCPMC11852786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.